Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Investment demonstrates confidence in America’s commitment to science and innovation
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
